Journées Pluridisciplinaires Hépatobiliaires, Pancréatiques et Digestives, Geneva
The health economic concept of cost-effectiveness ensures that the price of a pharmaceutical reflects its value. Can this price be applied within a high prevalence indication and help lead a majority of health systems the way to bankruptcy? When aiming to control drug expenditure, pharmaceutical pricing isn't the only issue to be raised. Publically funded innovation and pay-for-performance are concepts that offer stakeholders coping strategies for rising pharmaceutical spending and help ensure an available and accessible health care system.
Zur Präsentation (PDF, 3MB) (auf Englisch)